Absci Corporation reported a wider net loss and decreased revenue for Q3 2026, driven by increased R&D expenses for internal programs. Despite the negative financial results, the company maintains a strong cash position, projecting funding into H2 2028, which could mitigate immediate investor concerns about liquidity.
Absci Corporation's Q3 2026 earnings report shows a significant widening of its net loss to $33.3 million from $28.7 million year-over-year, alongside a revenue decrease from $0.4 million to $0.3 million. This deterioration in financial performance is primarily attributed to increased research and development expenses, particularly for the advancement of internal programs like ABS-201. While the negative earnings and revenue trends are concerning in the short term, the company's strong cash position of $173.7 million, projected to fund operations into the second half of 2028, provides a crucial buffer. For traders, the immediate reaction might be negative due to the poor financial results, but the extended cash runway could offer some stability, suggesting that the long-term outlook hinges on the success of their R&D pipeline rather than immediate liquidity concerns.